| Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small … M Joerger, J Von Pawel, S Kraff, JR Fischer, W Eberhardt, TC Gauler, ... Annals of Oncology 27 (10), 1895-1902, 2016 | 84 | 2016 |
| Semimechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for chemotherapy-induced cumulative neutropenia A Henrich, M Joerger, S Kraff, U Jaehde, W Huisinga, C Kloft, ... Journal of Pharmacology and Experimental Therapeutics 362 (2), 347-358, 2017 | 28 | 2017 |
| Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis U Schilling, A Henrich, C Muehlan, A Krause, J Dingemanse, M Ufer Clinical Drug Investigation 41 (8), 711-721, 2021 | 15 | 2021 |
| A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker C Huynh, A Henrich, DS Strasser, ML Boof, M Al‐Ibrahim, ... Clinical Pharmacology & Therapeutics 109 (6), 1648-1659, 2021 | 10 | 2021 |
| Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists A Henrich, CH Claussen, J Dingemanse, A Krause CPT: pharmacometrics & systems pharmacology 10 (7), 735-747, 2021 | 7 | 2021 |
| Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non–Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors FW Ojara, A Henrich, N Frances, W Huisinga, N Hartung, M Joerger, ... Journal of Pharmacology and Experimental Therapeutics 375 (3), 430-438, 2020 | 6 | 2020 |
| PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT A Henrich, PE Juif, J Dingemanse, A Krause Journal of Pharmacokinetics and Pharmacodynamics 48 (2), 213-224, 2021 | 5 | 2021 |
| Pharmacometric modelling and simulation to optimise paclitaxel combination therapy based on pharmacokinetics, cumulative neutropenia and efficacy A Henrich Freie Universitaet Berlin, 2017 | 4 | 2017 |
| A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients FW Ojara, A Henrich, N Frances, YM Nassar, W Huisinga, N Hartung, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1714-1725, 2023 | 3 | 2023 |
| Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small … M Joerger, J Von Pawel, S Kraff, JR Fischer, W Eberhardt, TC Gauler, ... 2015 ASCO Annual Meeting (May 29–June 2, 2015), Abstract 146973, 2015 | 3 | 2015 |
| Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies S Bianzano, A Henrich, L Herich, B Kalsch, D Sarubbi, F Seitz, T Forst Metabolism 143, 155550, 2023 | 2 | 2023 |
| Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists C Hsin, J Dingemanse, A Henrich, C Bernaud, M Gehin, A Krause Biomolecules 13 (9), 1365, 2023 | 1 | 2023 |
| DARIDOREXANT, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST, DOES NOT PROLONG THE QT INTERVAL DURATION FOLLOWING BEDTIME DOSING: RESULTS FROM A THOROUGH QT STUDY. U Schilling, A Henrich, A Krause, J Dingemanse, M Ufer CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S21-S21, 2021 | 1 | 2021 |
| A THOROUGH QT STUDY WITH CLAZOSENTAN, A SELECTIVE ENDOTHELIN A RECEPTOR ANTAGONIST. P Juif, A Henrich, A Krause, M Ufer, J Dingemanse CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S111-S111, 2020 | 1 | 2020 |
| Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the … M Joerger, J Von Pawel, S Kraff, JR Fischer, T Gauler, L Mueller, ... European Journal of Cancer 3 (51), S618, 2015 | 1 | 2015 |
| Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) S Buatois, K Benkali, A Henrich, F Jaminion, Y Zhang, A Sostelly Blood 140 (Supplement 1), 2918-2920, 2022 | | 2022 |
| 2022 WCoP Abstracts (vol 11, pg S9, 2022) FW Ojara, A Henrich, N Hartung, W Huisinga, M Joerger, C Kloft CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 11 (10), 1393-1393, 2022 | | 2022 |
| A First-in-Class CXCR7 Antagonist Increases Plasma Concentrations of the Target Engagement Biomarker CXCL12 in a Multi-Purpose First-in-Human Study C Huynh, A Henrich, DS Strasser, M Boof, M Al-Ibrahim, ... MULTIPLE SCLEROSIS JOURNAL 27 (1_ SUPPL), 34-34, 2021 | | 2021 |
| DECIPHERING MECHANISMS LEADING TO QT HYSTERESIS IN THE CONTEXT OF A THOROUGH QT STUDY WITH CLAZOSENTAN: INFLUENCE OF FOOD, ADVERSE EVENTS, AND OTHER FACTORS. P Juif, A Henrich, A Krause, M Ufer, J Dingemanse CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S111-S112, 2020 | | 2020 |
| The Case for an Unblinded Modeler in Early Clinical Development A Krause, A Henrich, J Dingemanse The Journal of Clinical Pharmacology 60 (3), 369-377, 2020 | | 2020 |
Andreas KrauseChief Scientific Officer, CPP at Simulations PlusVerified email at elmo.ch
